Antibody News and Research RSS Feed - Antibody News and Research

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.
Novel treatments show promising results in patients with different hematologic disorders

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders. [More]
Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]
Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Oncologists examine efficacy of rose bengal against cancer

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma. [More]
InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol. [More]
AYOXXA Biosystems closes third round of Series B financing

AYOXXA Biosystems closes third round of Series B financing

AYOXXA Biosystems GmbH, an international biotechnology company, announces the closing of a third round of Series B financing, bringing the total amount raised to 11.3 Mio. EUR in 2014. [More]
New blood test could help detect cold-related asthma risk

New blood test could help detect cold-related asthma risk

People who have asthma generally suffer worse with colds caused by rhinoviruses than other people do. There are also asthmatics and patients with the severe lung condition COPD in whom the cold virus can trigger serious flare-ups of their condition. A team of researchers from the Institute of Pathophysiology and Allergy Research at the MedUni Vienna has now discovered how this risk group can be filtered out using a blood test. [More]
Researchers develop low-cost, electricity-free device for detecting DNA of infectious pathogens

Researchers develop low-cost, electricity-free device for detecting DNA of infectious pathogens

Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers funded by the National Institutes of Health have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1. [More]
VE-PTP potential treatment target for retinal and choroidal vascular diseases

VE-PTP potential treatment target for retinal and choroidal vascular diseases

Targeting vascular endothelial-protein tyrosine phosphatase, which negatively regulates TIE2 activation, could help to stabilise retinal and choroidal blood vessels, researchers report. [More]
Cultrex® Embryoid Body Formation Kit introduced by AMSBIO

Cultrex® Embryoid Body Formation Kit introduced by AMSBIO

AMSBIO, experts in extracellular matrices, have introduced the Cultrex® Embryoid Body Formation Kit to generate consistent, reproducible and identical in size embryoid bodies. It has been qualified to form embryoid bodies from human pluripotent stem cells. Embryoid bodies are finding increasing use in regenerative medicine, in-vitro screening and as a model of embryonic development. [More]
Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease. [More]
Study provides proof of concept for developing antibodies against human pathogens

Study provides proof of concept for developing antibodies against human pathogens

Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in today's online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens. [More]
Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine. [More]
Lithium therapy duration not linked to thyroid effects

Lithium therapy duration not linked to thyroid effects

The risk of altered thyroid function does not increase with duration of lithium treatment in patients with bipolar disorder, research suggests. [More]
Ebola vaccine shows promising results in human trial

Ebola vaccine shows promising results in human trial

An experimental vaccine against the Ebola virus has proved effective and well-tolerated in the first human trial of a candidate Ebola drug. [More]
Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million. [More]
Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland. [More]
Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years. [More]
CARsgen announces completion of series A financing

CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund. [More]